Powered by

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Journey From Target to T Cell Product: A Platform to Identify Opportunities and Overcome Challenges, 2018 by DelveInsight

Jan 17, 2019 - PR Newswire

PR Newswire

Chimeric Antigen Receptor (CAR-T) - Market Scenario Collaborations, Opportunities, Pipeline development, Pricing and Reimbursement Policies, Market Potential, Unmet Needs etc.


CAR-T therapyinvolves collection of T-cells from patient's own immune system and infuse these genetically engineered cells back to patient's body to target the cancer. The application of co-stimulatory domains and safety switches in the existing CAR T cell technology resulted...